Bacterial surface proteins and vaccines

Guido Grandi

Address: Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100, Siena, Italy

Email: guido.grandi@novartis.com

1000 Biology Reports 2010, **2**:36 (doi:10.3410/B2-36)

The electronic version of this article is the complete one and can be found at: <http://1000.com/reports/biology/content/2/36>

Abstract

Surface-associated proteins play a key role in bacterial physiology and pathogenesis and are the major targets for vaccine development. Recent advances in defining the proteins associated with, and protruding out of, bacterial cells to a high level of accuracy are substantially contributing to accelerating the process of vaccine target identification and development.

Introduction and context

Genomic era and high-throughput technologies represent a turning point in vaccine discovery. The ability to sequence whole genomes and produce hundreds of recombinant proteins rapidly and efficiently has enabled almost entire bacterial proteomes to be scanned by *in vivo* and *in vitro* assays to identify the few protective antigens that can be included in vaccine formulations.

The first 'from-genome-to-vaccine' approach was pioneered by Stephen Johnston and colleagues [1], who constructed a plasmid library of the whole *Mycoplasma* genome and used it with DNA immunization to select the genes that protect mice against *Mycoplasma* challenge. Although the approach was not further pursued because of the inefficiency of DNA immunization when applied in high-throughput modalities, it represents a hallmark in vaccinology in that it has set the basis for subsequent, more effective strategies. One of these strategies involves the cloning and expression of a large fraction of the bacterial protein repertoire and the screening of each purified recombinant protein in appropriate 'surrogate of protection' assays. This approach was first attempted by Ling Lissolo and coworkers with uncertain results [2] but subsequently proved to be extremely effective by Pizza *et al.* [3], Maione *et al.* [4] and Stranger-Jones *et al.* [5] for an increasing number of pathogens. Vaccines developed following this strategy are currently in advanced clinical studies [6] and close to reaching the market. A second approach involves the shotgun cloning

of the whole genome of a given pathogen such that *Escherichia coli* expression libraries are generated in which clones express protein domains on their surface. The expression libraries are then screened with sera from patients infected by the pathogen of interest and the identified immunogenic proteins are tested for their capacity to elicit protective immunity in animal models [7].

The main limitation of the above technologies is that for them to be effective, several hundreds of proteins have to be tested in extremely time-consuming and labor-intensive protection assays, which usually involve animal immunization and challenge.

From an inspection of all antibacterial subunit-based vaccines either on the market or in advanced phases of development, it emerges that their components fall into the categories of secreted toxins or abundantly expressed, surface exposed molecules. Therefore, should effective methods capable of discriminating these molecules from the plethora of bacterial components become available, the development of new vaccines would be greatly accelerated.

Major recent advances

Today, bioinformatics tools are available to predict surface proteins in bacteria (see [8] and references therein). However, *in silico* analyses are still incapable of providing solid quantitative information on surface

protein expression, a severe limitation for vaccine development.

Several experimental procedures have been described for the identification of bacterial surface-associated proteins (reviewed in [9]). They are generally based on (a) chemical-physical methods to fractionate the different cellular compartments, (b) separation of membrane- and cell-wall-enriched fractions by gel electrophoresis or chromatography, and (c) mass spectrometry analysis of resolved fractions for protein identification.

In general, these approaches suffer two major limitations. First, fractionation methods aimed at separating the membrane fraction from the other cellular compartments are only partially efficient, with the result that several cytoplasmic proteins usually contaminate the protein mixture undergoing mass spectrometry analysis. Second, most of the methods developed do not provide information on the topological organization of the proteins associated with, or embedded in, the bacterial membrane. This information is particularly relevant for vaccine applications because the protein domains protruding out of the surface are those involved in the interaction with the host immune system.

Other methods for surface protein characterization involve selective biotinylation of whole bacteria with different biotinylating agents and subsequent mass spectrometry analysis of labeled proteins [10-14]. Although quite informative, these methods also suffer from the limitations of being poorly quantitative and selective.

Recently, two strategies have been proposed that at least partially overcome the above mentioned limitations. The first of these strategies has been designed for surface-exposed protein identification in Gram-positive bacteria. It involves the enzymatic 'shaving' of the bacterial surface with proteolytic enzymes under conditions that preserve the integrity and viability of bacterial cells. After digestion, the released peptides are separated from the 'shaved' bacteria and subjected to mass spectrometry for protein identification. The approach has been successfully applied in surface protein identification of group A [15,16] and group B *Streptococcus* [17]. In most cases, the presence of the proteins on the bacterial surface has been confirmed by demonstrating that antibodies against the recombinant forms of the identified proteins bind live bacteria, as revealed by fluorescence-activated cell sorting analysis [15]. One key aspect of this approach is that very little contamination with cytoplasmic proteins occurs; therefore, the proteins identified by mass spectrometry are *bona fide* surface-exposed proteins. In addition, since

only the protruding domains are accessible to proteases, the proteolytic peptides generated by the enzymatic treatment belong to the exposed part of the proteins; their characterization thus provides useful information on the topological organization of each identified protein [15,17].

In Gram-negative bacteria, the 'shaving' strategy is difficult to apply because of the relative fragility of the cells, which tend to die during protease treatment. For these bacteria a different approach has been recently developed that exploits their natural propensity to release outer membrane vesicles (OMVs) [18,19]. If specific mutations are selected, the amount of released OMVs – usually too small for practical purposes – can substantially increase and reach values of several milligrams (in protein content) per liter of culture [20,21]. Because of their small size (50-100 nm in diameter), OMVs can be easily separated from the bacterial cells by centrifugation or ultrafiltration (or both) and then subjected to mass spectrometry analysis for protein identification.

The proteome characterization of OMVs from a *Neisseria meningitidis* group B isolate and from a pathogenic *E. coli* strain has been reported recently [21,22]. The data show that OMVs almost exclusively contain outer membrane proteins and few periplasmic proteins, exactly as expected considering that they are generated through a 'budding out' of the outer membrane [20]. Interestingly, preliminary data indicate that, in contrast to parent cells, OMVs can be shaved with proteases without impairing their integrity, thus allowing topological studies of surface exposed proteins (Berlanda Scorza, unpublished data).

With these newly developed methods, accurate maps of bacterial surfaces describing protein organization in both topological and quantitative terms will soon be available. The data already generated show that the number of exposed membrane proteins expressed to a sufficiently high level to become the target of protective immune responses is limited to a few tens. As experimentally demonstrated, among them are to be found most, if not all, future vaccines.

Future directions

Two major aspects remain to be addressed in surface proteome analysis that might have important implications in future vaccine development. First, it is well known that, depending on environmental conditions, bacteria modulate their surface protein organization. So far, surface proteomes have been characterized only under specific and often artificial conditions. Therefore,

defining the dynamics of protein appearance and disappearance on the bacterial surface will provide important insights in bacterial physiology and pathogenesis. Second, it is expected that certain surface-exposed proteins interact and constitute functional protein complexes. So far, very little is known about which protein complexes are formed on the bacterial surface and this is a field that awaits future investigation.

Abbreviation

OMV, outer membrane vesicle.

Competing interests

The author declares that he has no competing interests.

References

- Barry MA, Lay WC, Johnston SA: **Protection against mycoplasma infection using expression-library immunization.** *Nature* 1995, **377**:632-5.
 - Grandi G: **Antibacterial vaccine design using genomics and proteomics.** *Trends Biotechnol* 2001, **19**:181-8.
 - Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL, Luzzi E, Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, Scarselli M, Storni E, Zuo P, Broeker M, Hundt E, Knapp B, Blair E, Mason T, Tettelin H, Hood DW, Jeffries AC, et al.: **Identification of vaccine candidates against serogroup B *Meningococcus* by whole-genome sequencing.** *Science* 2000, **287**:1816-20.
 - Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, Tettelin H, Brettoni C, Iacobini ET, Rosini R, D'Agostino N, Miorin L, Buccato S, Mariani M, Galli G, Nogaretto R, Nardi Dei V, Vegni F, Fraser C, Mancuso G, Teti G, Madoff LC, Paoletti LC, Rappuoli R, Kasper DL, Telford JL, Grandi G: **Identification of a universal Group B *Streptococcus* vaccine by multiple genome screen.** *Science* 2005, **309**:148-50.
 - Stranger-Jones YK, Bae T, Schneewind O: **Vaccine assembly from surface proteins of *Staphylococcus aureus*.** *Proc Natl Acad Sci U S A* 2006, **103**:16942-7.
- F1000 Factor 6.0 Must Read
Evaluated by Vivek Kapur 17 Jan 2007
- Giuliani MM: **A universal vaccine for serogroup B *Meningococcus*.** *Proc Natl Acad Sci U S A* 2006, **102**:10834-9.
 - Etz H: **Identification of *in vivo* expressed vaccine candidate antigens from *Staphylococcus aureus*.** *Proc Natl Acad Sci U S A* 2002, **99**:6573-8.
- F1000 Factor 3.0 Recommended
Evaluated by Vishvanath Nene 25 Jun 2002
- Giombini E, Orsini M, Carrabino D, Tramontano A: **An automatic method for identifying surface proteins in bacteria: SLEP.** *BMC Bioinformatics* 2010, **11**:39.
 - Cordwell SJ: **Technologies for bacterial surface proteomics.** *Curr Opin Microbiol* 2006, **9**:320-9.
 - Sabarth N, Lamer S, Zimny-Arndt U, Jungblut PR, Meyer TF, Bumann D: **Identification of surface proteins of *Helicobacter pylori* by selective biotinylation, affinity purification and two-dimensional gel electrophoresis.** *J Biol Chem* 2002, **277**:27896-902.
 - Myers-Morales T, Cowan C, Gray ME, Wulff CR, Parker CE, Borchers CH, Straley SC: **Surface-focused biotinylation procedure identifies the *Yersinia pestis* catalase KatY as a membrane-associated but not surface-located protein.** *Appl Environ Microbiol* 2007, **73**:5750-9.
 - Ge Y, Rikihisa Y: **Surface-exposed proteins of *Ehrlichia chaffeensis*.** *Infect Immun* 2007, **73**:3833-41.
 - Harding SV, Sarkar-Tyson M, Smither SJ, Atkins TP, Oyston PC, Brown KA, Liu Y, Wait R, Titball RW: **The identification of surface proteins of *Burkholderia pseudomallei*.** *Vaccine* 2007, **25**:2664-72.
 - Gatlin CL, Pieper R, Huang S-T, Mongodin E, Gebregeorgis E, Parmar PP, Clark, Hamid Alami DJ, Papazisi L, Fleischmann RD, Gill SR, Peterson SN: **Proteomic profile of cell envelope-associated proteins from *Staphylococcus aureus*.** *Proteomics* 2006, **6**:1530-49.
 - Rodríguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, Mora M, Scarselli M, Doro F, Ferrari G, Garaguso I, Maggi T, Neumann A, Covre A, Telford JL, Grandi G: **Characterization and identification of vaccine candidate proteins through analysis of the Group A *Streptococcus* surface proteome.** *Nat Biotechnol* 2006, **24**:191-7.
- F1000 Factor 6.4 Must Read
Evaluated by Patricia C Weber 04 Apr 2006, Victor Nizet 25 Apr 2006
- Severin A, Nickbarg E, Wooters J, Quazi SA, Matsuka YV, Murphy E, Moutsatsos IK, Zagursky RJ, Olmsted SB: **Proteomic analysis and identification of *Streptococcus pyogenes* surface-associated proteins.** *J Bacteriol* 2007, **189**:1514-22.
 - Doro F, Liberatori S, Rodríguez-Ortega MJ, Rinaudo CD, Rosini R, Mora M, Scarselli M, Altindis E, D'Aurizio R, Stella M, Margarit I, Maione D, Telford JL, Norais N, Grandi G: **Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B *Streptococcus* hypervirulent strain COH1.** *Mol Cell Proteomics* 2009, **8**:1728-37.
 - Kuehn MJ, Kesty NC: **Bacterial outer membrane vesicles and the host-pathogen interaction.** *Genes Dev* 2005, **19**:2645-55.
 - Mashburn-Warren LM, Whiteley M: **Special delivery: vesicle trafficking in prokaryotes.** *Mol Microbiol* 2006, **61**:839-46.
 - Bernadac A, Gavioli M, Lazzaroni JC, Raina S, Llobès R: ***Escherichia coli* tol-pal mutants form outer membrane vesicles.** *J Bacteriol* 1998, **180**:4872-8.
 - Ferrari G, Garaguso I, Adu-Bobie J, Doro F, Taddei AR, Biolchi A, Brunelli B, Giuliani MM, Pizza M, Norais N, Grandi G: **Outer membrane vesicles from group B *Neisseria meningitidis* Δgna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles.** *Proteomics* 2006, **6**:1856-66.
 - Berlanda Scorza F, Doro F, Rodríguez-Ortega MJ, Stella M, Liberatori S, Taddei AR, Serino L, Gomes Moriel D, Nesta B, Fontana MR, Spagnuolo A, Pizza M, Norais N, Grandi G: **Proteomics characterization of outer membrane vesicles from the extraintestinal pathogenic *Escherichia coli* ΔtolR IHE3034 mutant.** *Mol Cell Proteomics* 2008, **7**:473-85.